These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 27365426)

  • 1. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
    Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J
    Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
    Kilpivaara O; Mukherjee S; Schram AM; Wadleigh M; Mullally A; Ebert BL; Bass A; Marubayashi S; Heguy A; Garcia-Manero G; Kantarjian H; Offit K; Stone RM; Gilliland DG; Klein RJ; Levine RL
    Nat Genet; 2009 Apr; 41(4):455-9. PubMed ID: 19287384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
    Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
    BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
    Tapper W; Jones AV; Kralovics R; Harutyunyan AS; Zoi K; Leung W; Godfrey AL; Guglielmelli P; Callaway A; Ward D; Aranaz P; White HE; Waghorn K; Lin F; Chase A; Baxter EJ; Maclean C; Nangalia J; Chen E; Evans P; Short M; Jack A; Wallis L; Oscier D; Duncombe AS; Schuh A; Mead AJ; Griffiths M; Ewing J; Gale RE; Schnittger S; Haferlach T; Stegelmann F; Döhner K; Grallert H; Strauch K; Tanaka T; Bandinelli S; Giannopoulos A; Pieri L; Mannarelli C; Gisslinger H; Barosi G; Cazzola M; Reiter A; Harrison C; Campbell P; Green AR; Vannucchi A; Cross NC
    Nat Commun; 2015 Apr; 6():6691. PubMed ID: 25849990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
    Tanaka M; Yujiri T; Ito S; Okayama N; Takahashi T; Shinohara K; Azuno Y; Nawata R; Hinoda Y; Tanizawa Y
    Int J Hematol; 2013 Mar; 97(3):409-13. PubMed ID: 23430670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
    Matsuguma M; Yujiri T; Yamamoto K; Kajimura Y; Tokunaga Y; Tanaka M; Tanaka Y; Nakamura Y; Tanizawa Y
    Int J Hematol; 2019 Dec; 110(6):690-698. PubMed ID: 31571131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.
    Koh SP; Yip SP; Lee KK; Chan CC; Lau SM; Kho CS; Lau CK; Lin SY; Lau YM; Wong LG; Au KL; Wong KF; Chu RW; Yu PH; Chow EY; Leung KF; Tsoi WC; Yung BY
    BMC Genet; 2014 Dec; 15():147. PubMed ID: 25526816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
    Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
    Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
    Kim JT; Cho YG; Choi SI; Lee YJ; Kim HR; Jang SJ; Moon DS; Park YJ; Park G
    Korean J Lab Med; 2010 Dec; 30(6):567-74. PubMed ID: 21157140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
    Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
    Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR.
    Lu Y; Lin L; Lin J; Wu B; Cai G; Wang X; Ma X
    Ann Hematol; 2024 Sep; 103(9):3553-3562. PubMed ID: 39043913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
    Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
    Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.